Welcome to our dedicated page for Telix Pharmaceuticals SEC filings (Ticker: TLPPF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Telix Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Telix Pharmaceuticals's regulatory disclosures and financial reporting.
Telix Pharmaceuticals Ltd Group Chief Financial Officer Darren Charlton Smith has filed an initial ownership report showing a mix of ordinary shares and equity awards. He holds 10,810 Ordinary Shares directly. He also holds Performance Share Appreciation Rights over 45,449 and 32,463 Ordinary Shares at an exercise price of 6.1500 (Australian Dollars) expiring on October 24, 2027, and over 88,497 Ordinary Shares at an exercise price of 6.9000 expiring on December 31, 2027. In addition, he holds Share Rights over 1,111 Ordinary Shares expiring March 31, 2028 and 14,741 Ordinary Shares expiring March 31, 2029. Footnotes state that the PSARs and certain Share Rights were granted between October 2022 and March 2026 and became, or will become, vested and exercisable based on continued service and testing after the audited calendar year 2026 financial results.
Telix Pharmaceuticals Ltd director Nelson Mark Alexander has filed an initial Form 3 reporting his existing shareholdings. The filing shows indirect beneficial ownership of 3,628,750 Ordinary Shares held through MAN Holdings Pty Ltd, acting as trustee for the Nelson Hybrid Trust, of which he is a director and shareholder. This filing records his current position rather than any new share purchase or sale.
Telix Pharmaceuticals Ltd Group Chief Operating Officer Darren Joel Patti filed an initial ownership report showing existing equity interests in the company. The filing lists 25,558 Ordinary Shares held directly and 804 American Depositary Receipts, each convertible into one ordinary share according to the footnotes.
It also discloses derivative awards over ordinary shares, including Performance Share Appreciation Rights over 15,826 shares at $4.9500 per share and 27,448 shares at $6.9000, both with future expiration dates. Share Rights cover an additional 15,000, 12,541, and 15,000 underlying ordinary shares at a $0.0000 exercise price, with vesting and exercisability tied to continued service and future testing of results. The report records holdings only and does not show new market purchases or sales.
Telix Pharmaceuticals Limited filed Amendment No. 1 to its Form 20-F for the year ended December 31, 2025 to correct broken or incorrect hyperlinks for several exhibits, including Exhibits 4.17, 4.18, 8.1, 11.1, 12.1, 12.2, 13.1 and 13.2.
The amendment also adds new certifications from the Principal Executive Officer and Principal Financial Officer as required for such amendments, while leaving all previously filed financial statements and other disclosures unchanged. The number of ordinary shares outstanding as of December 31, 2025 was 338,777,049.
Telix Pharmaceuticals Ltd director Marie Elizabeth McDonald has filed an initial ownership report on Form 3. The filing shows an indirect holding of 3,719 Ordinary Shares held through Netwealth Investments Limited as custodian. This is a disclosure of existing holdings rather than a new share purchase or sale.
Telix Pharmaceuticals Ltd director Jann Elizabeth Skinner has filed an initial ownership report showing a significant indirect stake in the company. The Form 3 discloses indirect ownership of 595,000 Ordinary Shares held through Forellan Pty Limited, where Ms. Skinner is the sole director and shareholder. This filing records her existing position rather than new share purchases or sales.
Telix Pharmaceuticals Ltd managing director and Group CEO Christian Behrenbruch has filed an initial statement of holdings, detailing his equity and derivative interests in the company. He holds performance share appreciation rights over 93,114 ordinary shares at an exercise price of 4.9500 (Australian dollars) expiring on April 4, 2027, and further rights over 100,223 ordinary shares at 6.9000 expiring on December 31, 2027. These PSARs were granted in April 2022 and May 2023 and are already vested and exercisable.
Behrenbruch also holds share rights over 2,595 ordinary shares at a zero exercise price, expiring on March 31, 2028, which are likewise vested and exercisable. Indirectly, 20,675,000 ordinary shares are held through Elk River Holdings Pty Ltd, where he is the sole director and shareholder. In addition, he directly owns 400,000 American Depositary Receipts, each convertible into one ordinary share with no expiration date, and 254,006 ordinary shares held directly.
Telix Pharmaceuticals Limited has resubmitted a New Drug Application to the U.S. FDA for TLX101-Px (Pixclara), a PET imaging agent designed to help distinguish recurrent or progressive glioma from treatment-related brain changes in adult and pediatric patients.
The resubmission includes additional data and statistical analyses requested in a prior Complete Response Letter, alongside the original primary data set. TLX101-Px has Orphan Drug and Fast Track designations, reflecting its potential to address a significant unmet need, as there is currently no FDA-approved targeted amino acid PET agent for adult and pediatric brain cancer imaging in the U.S.
Telix Pharmaceuticals reported that Part 1 of its ProstACT Global Phase 3 study for TLX591-Tx in metastatic castration resistant prostate cancer achieved its primary objectives, showing an acceptable safety and tolerability profile with no new safety signals in 36 treated patients.
Patients received two doses of TLX591-Tx 14 days apart alongside standard therapies (enzalutamide, abiraterone or docetaxel) across three cohorts of 11, 11 and 14 patients. Most non-hematologic side effects were low grade, hematologic events were transient and manageable, and organ radiation exposure was below established safety limits. The study has already advanced into Part 2 outside the U.S., and Telix plans to present Part 1 data to the FDA to seek an IND amendment to expand Part 2 in the U.S.
Telix Pharmaceuticals files its annual report detailing a growing commercial radiopharmaceutical business alongside continued losses and regulatory risk. The company reported a loss after tax of $7.1 million and net operating cash outflow of $17.3 million for the year, with an accumulated deficit of $154.5 million. As of December 31, 2025, Telix held $141.9 million in cash and cash equivalents and had $426.1 million of 2.375% unsecured convertible bonds due 2029, plus $10.3 million of other debt, against 338,777,049 ordinary shares outstanding.
The business now relies heavily on two approved imaging products, Illuccix and Gozellix, which are commercial in multiple jurisdictions. However, key pipeline programs have faced regulatory setbacks: TLX250‑Px and TLX101‑Px each received FDA Complete Response Letters requiring additional chemistry, manufacturing, controls and clinical evidence, and both are being prepared for resubmission. The Phase 3 ProstACT Global trial of therapeutic candidate TLX591‑Tx is underway. Management highlights the need for potential additional capital, execution of its acquisition integrations, and careful control of leverage while advancing an expanding clinical and commercial footprint.